TRIAL DETAIL

Phase 1 Study of OSI-930 in Cancer Patients

Drug:
Trial Name:
Phase 1 Study of OSI-930 in Cancer Patients
NCT#:
Conditions:
Solid Tumors Sarcoma
Status:
Completed
Phase:
1
Start Date 04/01/2006
Age of Trial (yrs) 18.1
Treatment Phase:
Gleevec-resistant
Drug Category:
KIT inhibitor VEGFR inhibitor (TKI)
Strategy:
Block KIT
Trial Type:
GIST not specified. GIST patients known to be enrolled.
Other Protocol IDs:
OSI-930-102
Sponsor:
Astellas Pharma Inc
Patient Contact:
Emerging Med
Contact email:
ContactUs@EmergingMed.com
Contact Phone:
(877) 601-8601
Randomized:
IV or Oral:
Oral
Trial Notes:
This phase I trial is for solid tumors. Because OSI-930 inhibits KIT signaling, it is hoped that it may be beneficial in GIST.
In addition to inhibiting KIT, OSI-930 inhibits the VEGF receptors.
OSI-930 is manufactured by OSI pharmaceuticals. It has previously completed phase I testing in healthy volunteers.
Other contact info: OSIP Medical Informaiton 800.572.1932, x7821 medical-information@osip.com

Trial Links
 
 
 

Trial Results
 
 

Drug Information
ASCO search on OSI-930
 
OSI homepage
 
The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
 
Full text article - OSI-930: A novel selective inhibitor of KIT and Kinase insert domain receptro TKs with antitumor activity in mouse Xenograft models -1 Garton et al,
 
Groundbreaking Agreement Brings OSI-930 to China
 
Simcere and OSI Pharmaceuticals to market KDR/Kit inhibitor OSI-930 in China
 
OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models (PDF)
 
First in human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies
 

Trial Sites

Name
Address
City
State
Zip
Country
Downs Rd
Sutton
Surrey
SM2 5PT
UK
450 Brookline Ave
Boston
MA
02215-5450
USA
1665 N. Ursula St.
Aurora
CO
80045
USA